Insulet Corporation

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 11:53:47 2024-04-19 am EDT			5-day change	1st Jan Change
163.2 ^USD	-0.93%		-6.98%	-24.88%

Mar. 20	US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady	MT
Mar. 20	Insulet Names Ana Maria Chadwick Finance Chief	MT

Insulet Corporation Announces Revenue Guidance for the Quarter Ending June 30, 2021

May 06, 2021 at 02:01 pm EDT

Insulet Corporation announced that for the quarter ending June 30, 2021, the Company expects revenue growth of 10% to 14%.

Latest news about Insulet Corporation

US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady	Mar. 20	MT
Insulet Names Ana Maria Chadwick Finance Chief	Mar. 20	MT
Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024	Mar. 20	CI
Insulet Corporation Announces Chief Financial Officer Changes	Mar. 20	CI
3M Board Approves Healthcare Unit Spinoff -- Update	Mar. 08	DJ
Transcript : Insulet Corporation - Special Call	Mar. 08
Insulet Says Trial Shows Omnipod 5 Insulin Delivery System Superior to Pump Therapy	Mar. 08	MT
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)	Mar. 08	CI
Transcript : Insulet Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:35 AM	Mar. 05
Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes	Mar. 05	CI
Stocks in motion: Alphabet drops as Microsoft signs another AI partnership	Feb. 26
Barclays Trims Insulet Price Target to $213 From $214, Maintains Equal Weight Rating	Feb. 26	MT
Insulet forecasts weak annual revenue growth; shares drop	Feb. 22	RE
Insulet Q4 Adjusted Earnings, Revenue Increase; Q1, 2024 Revenue Outlook Set	Feb. 22	MT
Transcript : Insulet Corporation, Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (PODD) INSULET CORPORATION Posts Q4 EPS $1.40, vs. Street Est of $0.66	Feb. 22	MT
Earnings Flash (PODD) INSULET CORPORATION Reports Q4 Revenue $509.8M, vs. Street Est of $461.1M	Feb. 22	MT
Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Insulet beats quarterly profit estimates on strong demand for insulin pumps	Feb. 22	RE
Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024	Feb. 22	CI
MORNING BID AMERICAS-AI 'tipping point' sends Nvidia, Nasdaq, Nikkei north	Feb. 22	RE
Insulet's Omnipod 5 Receives CE Mark for Abbott FreeStyle Libre 2 Plus Integration	Feb. 07	MT
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
UBS Raises Insulet Price Target to $211 From $175, Maintains Neutral Rating	Jan. 22	MT
Insulet Corporation Announces Board Changes	Jan. 18	CI

Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Insulet Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

164.7 USD

Average target price

236.3 USD

Spread / Average Target

+43.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
INSULET CORPORATION	-24.88%	11.53B
ABBOTT LABORATORIES	-2.73%	183B
MEDTRONIC PLC	-3.63%	105B
DEXCOM, INC.	+5.90%	51.77B
CENCORA, INC.	+16.05%	47.29B
HOYA CORPORATION	-1.73%	40.2B
WEST PHARMACEUTICAL SERVICES, INC.	+7.08%	27.62B
METTLER-TOLEDO INTERNATIONAL, INC.	-1.37%	25.51B
TERUMO CORPORATION	+9.84%	24.73B
ZIMMER BIOMET HOLDINGS, INC.	-2.00%	24.52B

Other Medical Equipment, Supplies & Distribution